georgeclerk
argenx SE (ARGX) traded lower on Thursday as Baird downgraded the Dutch biotech, citing concerns over its valuation following a late-stage trial setback for its best-selling therapy, Vyvgart, this week.
ARGX shares dropped on Monday after the company announced that